FluoGuide: Shining light on a mispriced opportunity
Redeye returns with an update on FluoGuide, which is set to enter a catalyst-rich 2026 with multiple key milestones ahead. In conjunction with...
84 Views
FluoGuide: FG001 receives Fast Track designation
Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Glioma. This gives positive regulatory momentum...
86 Views
Fluoguide (Q4 Initial take): Key milestones to drive value in 2026
Redeye provides a short comment on Fluoguide’s Q4 earnings and the company's outlook for 2026. The report contained no major surprises, which is...
81 Views
Fluoguide: Adjusting estimates for directed share issue
Redeye adjusts its estimates and valuation for Fluoguide's directed share issue.
89 Views
Fluoguide Q1 2022: Our comment
Redeye briefly comments on Fluoguide’s Q1 2022 report. We believe the company has executed some important milestones during the first five months...
86 Views